Alcohol Withdrawal Clinical Trial
Official title:
Oxytocin Treatment of Alcohol Withdrawal
Purpose: Test whether intranasal administration of the neuropeptide, oxytocin, is effective
in decreasing alcohol withdrawal symptoms, the number of bouts of withdrawal requiring
standard medication treatment (lorazepam) and the amount of lorazepam required to control
withdrawal bouts in individuals undergoing medical detoxification. Also, determine rates of
subject recruitment and retention in the inpatient setting.
Participants: 80 alcohol dependent patients, 18-65 years of age, admitted for medical
detoxification.
Procedures (methods): Subjects will be inpatients undergoing medical detoxification from
alcohol. Oxytocin or placebo will be administered in a nasal spray twice daily in a
randomized, double blind manner for three days. Withdrawal symptoms will be measured
routinely at q4 hours and prn for length of hospital stay. Lorazepam will be given whenever
withdrawal symptoms increase above specific parameters.
Study Design: This will be a double-blind, placebo controlled comparison of the efficacy of
twice daily intranasal administration of oxytocin and placebo (saline) in reducing alcohol
withdrawal symptoms, the number of bouts of withdrawal during which symptoms are of
sufficient magnitude requiring prn lorazepam treatment (see definitions below) and the
amount of lorazepam required to resolve withdrawal bouts. Treatment group assignment will be
random within each sex. Subjects will be patients admitted to (University of North Carolina
(UNC) Hospitals or the Dix Clinical Research Unit (CRU) for medical detoxification. Each
treatment group will be composed of up to 40 subjects. Dr. Hamer, the study statistician,
will construct a randomization plan to randomize 80 subjects to 2 groups of 40 subjects each
with a blocksize of 4. This will be a permuted blocksize as this is a blind study.
Procedures: Most patients who are admitted to the UNC Neuroscience Hospital Crisis
Stabilization Unit, UNC Hospitals Family Practice or Hospitalist Services, or the Dix CRU
for medical detoxification from alcohol will come in through the UNC Hospitals Emergency
Department or Dorothea Dix Screening and Admissions during the late evening or early
morning. Physical examination, medical and psychiatric history and lab tests (including
complete blood count [CBC], magnesium, sodium, potassium, [blood urea nitrogen] BUN,
creatinine, glucose, albumin, liver functions tests [ALT, AST, LDH, GGT], throid-stimulating
hormone (TSH), B12, folate, urinalysis, urine toxicology screen and pregnancy test) are
routinely obtained by the emergency department (ED)/ Dorothea Dix Screening and Admissions
and/or inpatient unit during the admission process. Possibly in the UNC Hospitals ED/
Dorothea Dix Screening and Admissions and definitely after admission to these units,
patients will have their vital signs (VSs) measured and their withdrawal symptoms quantified
using the revised Clinical Institute Withdrawal Assessment for Alcohol scale (CIWA-Ar scale,
Sullivan et al 1989) on the schedule in the standard alcohol detoxification order set in the
UNC Hospital electronic medical records system (CPOE) system. The CRU at Dorothea Dix will
use a hard copy version of the CIWA used in the CPOE at UNC Hospitals.
After consent is obtained, subjects will be randomly assigned to a treatment group (oxytocin
or placebo). Prior to receiving their first intranasal treatment, an ECG will be obtained
and blood drawn to obtain serum for assay of cytokine and allopregnanolone concentrations.
Subjects also will rate their symptoms using the Alcohol Withdrawal Symptom Checklist (AWSC,
Pittman et al 2007) prior to receiving their first test dose. These procedures will be
done/overseen by research nurses or physicians. Subjects will usually receive their first
intranasal test dose between 1000 and 1200 hours and will consist of 6 insufflations of
Syntocinon Spray (approximately 24 IU) or placebo, with each insufflation given 30 seconds
apart and alternating between nostrils. Test doses will be taken again at 1700 hr later that
day (Admission Day 1) and at 0900 and 1700 hr on Admission Days 2 and 3. Oxytocin test
treatments will be administered from 5 ml intranasal spray vials designed to deliver 0.1 ml
metered volume per insufflation. The placebo treatments will be administered from 60 ml
intranasal spray vials (each containing 30ml of solution) also designed to deliver 0.1ml
metered volume per insufflation. Vials containing oxytocin and placebo spray will be blind
labeled by the UNC Investigational Drug Service or the Dorothea Dix Hospital pharmacy.
Research nurses or physicians will oversee subject self-administration of all intranasal
test doses. After enrollment on admission day 1 and in the morning on admission days 2 and
3, subjects will be given multiple copies of the AWSC questionnaire and requested to
complete one each time the unit nurses do CIWA ratings. These questionnaires will be
retrieved by research staff the following morning. Shortly after the morning test dose on
admission days 2 and 3, subjects will complete the Alcohol Craving Visual Analog Scales
(ACVAS), the Penn Alcohol Craving Scale, and the Profile of Mood States (McNair et al,
1971). On these same admission days, research nurses will also draw (and subsequently
process) blood serum samples to assay cytokine and allopregnanolone concentrations shortly
after the morning test dose. Additional blood will be drawn after the morning test dose on
admission day 2 to obtain serum for tests to be run in McLendon Laboratories (magnesium,
chloride, calcium, sodium, potassium, BUN, creatinine, and liver function tests). Another
electrocardiogram (ECG) will also be obtained shortly after the morning test treatment on
admission day 2. Research staff will retrieve on a daily basis CIWA ratings and vital sign
measurements obtained on each subject from their electronic medical record.
In all subjects, PRN lorazepam doses will be administered by mouth (PO) or intravenously
(IV) (if subjects cannot take medication PO) whenever CIWA ratings are > 14 per the protocol
in the standard alcohol detoxification order set in the UNC Hospital CPOE system. Lorazepam
doses (1 - 4 mg) and frequency (q 2 -6 h) will be adjusted based on the severity of
withdrawal symptoms. This same order set will be employed at the Dorothea Dix CRU.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03916939 -
Osteopathic Treatment to Alcohol Withdrawal Syndrome
|
N/A | |
Completed |
NCT04858490 -
Remote Treatment of Alcohol Withdrawal
|
N/A | |
Not yet recruiting |
NCT04997330 -
Evaluation of Bilateral HF-rTMS on Abstinence in Alcohol Use Disorder Patients With Executive Dysfunction
|
N/A | |
Recruiting |
NCT04876443 -
Impact of COVID-19 Outbreak on the Alcohol Consumption in Patients With Alcohol-related Liver Disease (ICoLD)
|
||
Completed |
NCT05131334 -
Auricular Vagal Stimulation in Alcohol Craving
|
N/A | |
Completed |
NCT02349477 -
Gabapentin for Alcohol Relapse Prevention
|
Phase 2 | |
Terminated |
NCT01937364 -
Preventing Alcohol Withdrawal With Oral Baclofen
|
Phase 2 | |
Completed |
NCT05393544 -
Digitally Assisted Recovery Coach
|
N/A | |
Completed |
NCT00523185 -
A Comparison of Lorazepam and Diazepam in the Treatment of Alcohol Withdrawal
|
N/A | |
Completed |
NCT01573052 -
Gabapentin vs Chlordiazepoxide for Ambulatory Alcohol Withdrawal
|
Phase 4 | |
Enrolling by invitation |
NCT06173973 -
Effects of Ketone Supplementation on Acute Alcohol Withdrawal
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT03737864 -
NCARE, Transition to Recovery
|
N/A | |
Recruiting |
NCT03878225 -
Does a Ketogenic Dietary Supplement Reduce Alcohol Withdrawal Symptoms in Humans?
|
N/A | |
Terminated |
NCT03586089 -
Phenobarbital for Severe Acute Alcohol Withdrawal Syndrome
|
N/A | |
Recruiting |
NCT04156464 -
Phenobarbital vs Ativan for Alcohol Withdrawal in the Intensive Care Unit
|
Phase 4 | |
Completed |
NCT02251912 -
Oxytocin Treatment of Alcohol Dependence
|
Phase 2 | |
Completed |
NCT02202148 -
Liver Stiffness Measurement in Alcohol-dependent Subjects in Relation to Abstinence After Withdrawal
|
N/A | |
Recruiting |
NCT04793685 -
Prazosin for Alcohol Use Disorder With Withdrawal Symptoms
|
Phase 1/Phase 2 | |
Withdrawn |
NCT04159909 -
Using Transcutaneous Auricular Vagus Nerve Stimulation to Treat Acute Alcohol Withdrawal
|
N/A | |
Completed |
NCT05563350 -
Metabolism of Chlordiazepoxide in the Treatment of Alcohol Withdrawal Symptoms
|